What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced or Metastatic Urothelium Cancer
- Main trialPhase 3
- “The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors.”In the company’s words, NCT05754853 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Oct 2025 | A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer | |
| Phase 2/3Unknown | Sep 2023 | A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer | |
| Phase 2Unknown | Jun 2022 | A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | |
| Phase 2Unknown | Dec 2022 | A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer | |
| Phase 2Unknown | Dec 2022 | A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients | |
| Phase 2Unknown | Feb 2023 | A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) | |
| Phase 2Unknown | Dec 2023 | A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | |
| Phase 2Unknown | Dec 2023 | A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. | |
| Phase 1/2Unknown | 18 Oct 2022 | A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer | |
| Phase 1Unknown | Oct 2022 | A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026